|

Prasugrel Clinical Trials

3 actively recruiting trials across 1 location

▲ +1 trial since August 2026

Also known as: Efient

Pipeline

Phase 3: 1Phase 4: 2

Top Sponsors

  • University of Florida1
  • Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz1
  • Cardiocentro Ticino1

Indications

  • Heart Disease3
  • Coagulation Factors1
  • Antiplatelet Therapy1
  • Single Antiplatelet Therapy1
  • Percutaneous Coronary Intervention (PCI)1

Other2 trials

Dual Antiplatelet Therapy Strategies After Acute Myocardial Infarction Undergoing PCI: Prasugrel vs Ticagrelor & 12 Months vs 1-3 Months
Phase 4
Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty.
Phase 3

Jacksonville, Florida1 trial

Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)

University of Florida Health

Phase 4

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.